Chinese expert consensus on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors.
10.3760/cma.j.cn112138-20250919-00559
- Collective Name:National Clinical Research Center for Dermatologic and Immunologic Diseases (Peking Union Medical College Hospital);Chinese Association of Rheumatology and Immunology Physicians;Dermatology Professional Committee of Chinese Rehabilitation Medical Association
- Publication Type:Consensus Development Conference
- MeSH:
Humans;
Janus Kinase Inhibitors/therapeutic use*;
Consensus;
Inflammation/drug therapy*;
Inflammatory Bowel Diseases/drug therapy*;
East Asian People
- From:
Chinese Journal of Internal Medicine
2025;64(12):1187-1210
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, Janus kinase (JAK) inhibitors have been gradually approved for the treatment of immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, juvenile idiopathic arthritis, giant cell arteritis, atopic dermatitis, alopecia areata, psoriasis, and inflammatory bowel disease. To standardize the application of JAK inhibitors in IMIDs, the expert group of this consensus has formulated the Chinese expert consensus on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors, based on the latest research data, relevant guidelines, domestic and international literature, and clinical practice experience of the experts. This consensus provides a comprehensive introduction to treatment regimens, safety management, and medication use in specific populations, aiming to assist clinicians in making reasonable clinical decisions.
